Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Connect Biopharma Holdings ( (CNTB) ) is now available.
On May 14, 2025, Connect Biopharma announced the initiation of its Phase 2 Seabreeze STAT study for chronic obstructive pulmonary disease (COPD) after receiving FDA approval for the study protocol. This study will assess the safety and efficacy of rademikibart as an adjunct treatment for acute exacerbations in COPD patients with type 2 inflammation. The company aims to address the unmet need for rapid, effective treatment following acute exacerbations, with topline data expected in the first half of 2026. The study’s initiation follows promising results from a post-hoc analysis of a previous asthma study, indicating potential benefits for COPD patients, particularly those with elevated eosinophil counts.
The most recent analyst rating on (CNTB) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page.
Spark’s Take on CNTB Stock
According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral.
Connect Biopharma Holdings’ overall score reflects the challenges of unprofitability and negative cash flow despite recent revenue growth and a strong balance sheet. Technical indicators suggest a bearish trend, while the valuation highlights the risks typical of early-stage biotech firms. However, the positive corporate event regarding FDA support for Phase 2 trials offers a promising growth opportunity in the pipeline, improving the outlook.
To see Spark’s full report on CNTB stock, click here.
More about Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, aimed at addressing acute exacerbations in asthma and COPD, particularly for patients visiting emergency rooms annually.
Average Trading Volume: 115,338
Technical Sentiment Signal: Sell
Current Market Cap: $44.41M
Learn more about CNTB stock on TipRanks’ Stock Analysis page.